BIOKIN PHARMACEUTICAL(SH:688506)2024-01-02 07:36Group 1: Company Overview - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is involved in the development of innovative biopharmaceuticals targeting malignant tumors [1] - As of June 30, 2023, the company has a research team of 649 members, accounting for 30.06% of the total workforce [2] Group 2: Product Development - The company is focused on a dual-target antibody drug conjugate (ADC) that has broad tumor coverage and potential for future applications [2] - The company has accumulated over 800 Phase I tumor data cases covering more than 10 types of tumors [2] Group 3: Strategic Partnerships - Bristol-Myers Squibb (BMS) chose to collaborate with the company due to its extensive data and innovative approach in the ADC space [2] Group 4: Future Directions - The company plans to maintain its focus on new antibody technologies and will not extend its research into other fields [2] - The goal is to develop innovative biopharmaceuticals with breakthrough efficacy and global rights, establishing a leading position in the dual/multi-antibody product pipeline [2]